[HTML][HTML] G-protein-coupled receptors as therapeutic targets for glioblastoma

KF Byrne, A Pal, JF Curtin, JC Stephens… - Drug Discovery …, 2021 - Elsevier
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in
adults. Treatments include surgical resection, radiotherapy, and chemotherapy. Despite this …

[HTML][HTML] The phenomenon of multidrug resistance in glioblastomas

AN Chernov, DA Alaverdian, ES Galimova… - … /Oncology and Stem Cell …, 2021 - Elsevier
The most common and aggressive brain tumor in the adult population is glioblastoma
(GBM). The lifespan of patients does not exceed 22 months. One of the reasons for the low …

Old and new systemic immune-inflammation indexes are associated with overall survival of glioblastoma patients treated with radio-chemotherapy

F Pasqualetti, C Giampietro, N Montemurro, N Giannini… - Genes, 2022 - mdpi.com
Background. Systemic immunity and inflammation indexes (SI) derived from blood cells
have gained increasing attention in clinical oncology as potential biomarkers that are …

Glioblastoma and Internal Carotid Artery Calcium Score: A Possible Novel Prognostic Partnership?

F Pasqualetti, M Gabelloni, L Faggioni… - Journal of Clinical …, 2024 - mdpi.com
Purpose: Clinical evidence suggests an association between comorbidities and outcome in
patients with glioblastoma (GBM). We hypothesised that the internal carotid artery (ICA) …

Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy

F Pasqualetti, A Gonnelli, P Orlandi, E Palladino… - Investigational New …, 2021 - Springer
This study reports the results of a monocentric prospective analysis conducted with the aim
of evaluating the impact of XRCC1 rs25487, XRCC3 rs861539, XRCC3 rs1799794, RAD51 …

Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio …

F Pasqualetti, A Gonnelli, M Cantarella… - Investigational new …, 2018 - Springer
Glioblastoma (GBM) is the most frequent malignant primary brain tumor in adults and,
despite recent advances, the prognosis for this cancer remains dismal. The aims of this …

Different timing to use bevacizumab in patients with recurrent glioblastoma: early versus delayed administration

F Pasqualetti, A Gonnelli, A Molinari… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: In patients with recurrent glioblastoma, the best timing to administer
bevacizumab is not well addressed yet. In this study, we reported the results of a …

Melanocortin receptor-4 and glioblastoma cells: Effects of the selective antagonist ml00253764 alone and in combination with temozolomide in vitro and in vivo

F Vaglini, C Pardini, T Di Desidero, P Orlandi… - Molecular …, 2018 - Springer
Currently, no description of melanocortin receptor-4 (MC4R) expression or activity is
available in human cancer cells, including glioblastoma (GBM). The aim of this study is to …

[PDF][PDF] 谷胱甘肽S-转移酶P-1 基因遗传变异对接受替莫唑胺联合放疗的脑胶质瘤患者预后的影响

陈劲松, 林富, 朱双根, 范少平, 马建国, 李归宿 - 肿瘤预防与治疗, 2019 - cswog.net
目的: 替莫唑胺联合放疗在新诊断脑胶质瘤的辅助治疗中具有重要治疗地位, 谷胱甘肽S
转移酶P 1 (GlutathioneS TransferaseP 1, GSTP1) 在胶质瘤细胞外源性物质解毒过程中 …

The Impact of Melanocortin Receptor Ligands on Astrocyte Signalling and Metabolism

A Alkhalidi - 2025 - ore.exeter.ac.uk
Melanocortin peptides, which act on melanocortin receptors (MCRs), play multifaceted roles
in the body through various tissues and mechanisms that regulate physiological functions …